Immune Cell Gene Expression for Prostate Radiation Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting response to radiation therapy in prostate cancer are limited by heterogeneous cohorts, small sample sizes, and a lack of understanding of immune cell interactions with the tumor microenvironment, leading to insufficient predictive biomarkers.
Innovation Solution
Utilizing immune cell-specific gene expression, particularly of activated mast cells, NK cells, dendritic cells, macrophages, and T cells, to determine prognosis and identify patients likely to respond to radiation therapy by measuring gene expression levels and calculating immune cell types using computational methods like CIBERSORT.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If standard clinical parameters and molecular markers are used for patient stratification, then treatment guidance is provided, but prediction accuracy remains insufficient due to heterogeneous cohorts and small sample sizes
Solution Approach 1:
The patent transforms the approach by changing from traditional clinical parameters to immune cell-specific gene expression parameters. By measuring gene expression levels of specific immune cell types (mast cells, NK cells, dendritic cells, macrophages, T cells) and calculating immune cell type levels, the method achieves higher prediction accuracy for radiation therapy response without requiring larger sample sizes.
2Reliability
If traditional immunotherapy strategies are used, then treatment options are provided, but response rates remain low due to poor understanding of immune cell interactions with tumor microenvironment
Solution Approach 1:
The patent uses immune cell-specific gene expression profiles as an intermediary to bridge the gap between observable tumor characteristics and treatment response. By quantifying the levels of different immune cell types through gene expression analysis, the method provides actionable information about immune cell interactions with the tumor microenvironment, enabling more reliable prediction of radiation therapy response.
3Measurement precision
If comprehensive immune cell analysis is performed, then prediction accuracy improves, but method complexity increases
Solution Approach 1:
The patent extracts specific immune cell type information from complex tumor tissue samples by measuring gene expression levels of marker genes specific to each immune cell type. This extraction approach allows comprehensive immune cell analysis while maintaining manageable complexity, as it focuses on specific gene markers rather than attempting to analyze all cellular components of the tumor microenvironment.
Data Source
AI summary
Methods, systems, and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject are disclosed. In particular, the disclosure relates to the use of immune cell-specific gene expression in determining prognosis and identifying individuals in need of treatment for prostate cancer who will be responsive to radiation therapy.